1. Assessment of a Nano-Docetaxel Combined Treatment for Head and Neck Cancer
- Author
-
Gee Young Lee, Nicole C. Schmitt, Maya B. Cothran, Hadiyah-Nicole Green, Tamra S. McKenzie, Merry E. Sebelik, Mohamed Mubasher, Carrie E. Flanagan, and Badi El Osta
- Subjects
Programmed cell death ,Combination therapy ,business.industry ,Head and neck cancer ,therapies ,head and neck squamous cell carcinoma ,medicine.disease ,Head and neck squamous-cell carcinoma ,combination therapy ,Combined treatment ,Docetaxel ,oncology ,Cancer research ,docetaxel ,Medicine ,nanoparticles ,Dose reduction ,Viability assay ,business ,medicine.drug - Abstract
Objective: The combination of docetaxel (DTX) with Laser-Activated NanoTherapy (LANT), as a treatment for head and neck cancer (HNC), may enhance the therapeutic efficacy of lower doses of DTX, thereby minimizing the effective dosage, side effects and treatment times. Material and methods: Three HNSCC cell lines, Detroit 562, FaDu, and CAL 27, were treated with four combinations of DTX + LANT to evaluate DTX dose reduction and cell viability. Results: The 1 nM DTX + 5 nM LANT combination was the most effective treatment, increasing cell death over its corresponding DTX monotreatment with approximately 86.6%, 80.7%, and 92.1% cell death for Detroit 562, FaDu, and CAL 27, respectively. In Detroit 562, the 1 nM DTX + 5 nM LANT combination treatment resulted in the highest percentage of DTX dose reduction at 84.6%, in FaDu and CAL 27, the 0.5 nM DTX + 5 nM LANT combination treatment resulted in the highest percentage of DTX dose reduction at 78.2% and 82.4%, respectively. Conclusion: LANT may increase the therapeutic efficacy of DTX at significantly lower doses, which could improve patient outcomes.
- Published
- 2021
- Full Text
- View/download PDF